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Dear Editors,
Enhancement of social function is an important goal in the treatment of schizophrenia. To designate appropriate measures of real-world functioning, the Validation of Everyday Real-World Outcomes initiative recommended the Specific Levels of Functioning-Scale (SLOF). The SLOF has been developed as an interview-based assessment tool; the scores by clinicians are based on information from both patients and caregivers (Leifker et al., 2009 ). The SLOF covers interpersonal functioning, everyday activities, and vocational functioning (Schneider and Struening, 1983) .
Factors affecting SLOF scores evaluated objectively (by clinicians or caregivers) or subjectively (by patients) have been investigated. Durand et al. (2015) observed that scores on the SLOF rated by clinicians were correlated with performance on the UCSD Performance-based Skills Assessment-Brief (UPSA-B), representing daily-living skills, while scores reported by patients were associated with depression (Durand et al., 2015) . Specifically, Ermel et al. (2017) examined the discrepancy between caregiver-and patient-evaluated SLOF scores, and found its relationship with depressive emotion and work function (Ermel et al., 2017) .
However, little is known about other clinical factors affecting the judgment of his/her own real-world functioning. Specifically, we considered social cognition and metacognition may influence evaluation of social function. In fact, social cognition has been shown to mediate neurocognition and social function (Schmidt et al., 2011) , while metacognition has been associated with real-world functioning (Sumiyoshi et al., 2016) .
In this study, we sought to determine if social cognition and metacognition contribute to the difference between SLOF scores provided by patients and those by caregivers/clinicians. We hypothesized that social cognition, as measured by the Social Cognition Screening Questionnaire (SCSQ) (Roberts et al., 2011) and meta-cognition, as evaluated by the Beck Cognitive Insight-Scale (BCIS) (Beck et al., 2004) would explain the discrepancy between self-reporting and objectively-rated scores on the SLOF.
A total of 58 outpatients receiving antipsychotic drugs and 53 caregivers were enrolled from 10 institutes ( Table 1 ). The ethics committees of the participating institutions approved this study, and written informed consent was obtained. Results of analysis of other issues using this dataset have been reported (Sumiyoshi et al., 2016) We Multiple regression analysis (stepwise method) was conducted. Independent variables were scores on the UPSA-B, SCSQ (excluding Hostility subscale scores), BCIS (composite index), and Positive and Negative Syndrome Scale (five factors model). The SCSQ consists of five domains, i.e. verbal memory, schematic inference, theory of mind, metacognition, and hostility bias. Short fiction stories were read by testers, and participants are requested to answer questions relevant to these domains. Hostility was excluded because the direction of its score is opposite to those of other subscale scores, as has been reported (Kanie et al., 2014) . A higher SCSQ score represents better skills. The BCIS consists of the Self-Reflectiveness and Self-Certainty subscales, as reported by patients. These subscales, as well as the composite index, i.e. subtraction of the Self-Certainty subscale scores from the SelfReflectiveness subscale scores, are generally used, with higher indices representing better conditions.
The differences in SLOF scores (caregiver-reported SLOF scores minus patient-reported scores, and clinician-reported SLOF scores minus patient-reported scores) were used as dependent variables. A positive or negative difference indicates a higher or lower estimation by the patient of his/her real-world functioning, compared to the actual one. SLOF scores rated by caregivers were missing for five patients. Therefore, data from these subjects were excluded from multiple regression analyses using caregiver-reported SLOF scores.
The difference in SLOF scores between caregivers and patients was predicted by BCIS scores (B = 0.968, SE = 0.426, beta = 0.303, t = 2.272, p = 0.027, R 2 = 0.092), while that between clinicians and patients was predicted by SCSQ scores (B = 1.036, SE = 0.274, beta = 0.451, t = 3.778, p = 0.030, R 2 = 0.203). On the other hand, the difference in SLOF scores between caregivers and clinicians was not associated with any of the variables studied. The contribution of BCIS scores to the difference between SLOF scores by caregivers and those by patients indicates that the failure of patients to appropriately estimate their functional status may partly be explained by deficits of cognitive insight. In fact, SLOF scores evaluated by caregivers have been suggested to provide appropriate information on social function (Moritz and Woodward, 2007) . Further research on interventions targeting metacognition is warranted to assess its ability to improve self-estimation of real-world functioning in schizophrenia.
The discrepancy between SLOF scores evaluated by clinicians and those by patients was predicted by SCSQ scores. Domains of socialcognition estimated by the SCSQ include the ability to understand what others are thinking, i.e., theory of mind (Kanie et al., 2014) . Data from this study suggest some domains of social cognition, e.g. theory of mind, may help objectively evaluate one's own social function.
In conclusion, differences in the evaluation of social function among patients, caregivers, and clinicians may be explained by social cognition and metacognition of patients. These observations provide a clue to accurate evaluation of real-world functioning in patients with schizophrenia.
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